ArticleFrontiers in oncology2025
Additional prognostic value of the BCT score in ER+HER2- breast cancer patients receiving a 21-gene assay-guided adjuvant treatments.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Independent prognostic value of the gene-only BCT Score compared with the 21-gene recurrence score in ER+/HER2- early breast cancer.Frontiers in oncology · 2026Article
- Cost-effectiveness analysis of gene-expression-based prognostic tests for patients with early-stage breast cancer in South Korea.Cost effectiveness and resource allocation : C/E · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The 21-gene recurrence score (RS)-guided decision-making for adjuvant treatment has been utilized as a standard of care for early ER+HER2- breast cancer. We investigated a prognostic value of the Breast Cancer Test (BCT) score, a multigene assay incorporating clinical risk, in estrogen receptor (ER)+HER2- breast cancer patients receiving RS-guided adjuvant treatments, specifically focusing on chemotherapy-untreated patients with low RS. Methods: This multicenter cohort study included 759 patients who received RS-guided adjuvant treatment. The primary endpoint was recurrence-free survival (RFS), and the secondary endpoint was distant recurrence-free survival (DRFS). Results: At a median follow up of 85 months, the 7-year RFS was 92.9% (95% CI, 90.9%-94.9%). Among the 592 chemotherapy-untreated patients with low RS, the RFS differed significantly according to the BCT score ( Conclusions: Our study suggests the utility of the BCT score in stratifying the relapse risk among chemotherapy-untreated patients with a low RS, particularly in young women with an RS of 16-25 who are at risk for long-term recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.